News from atyr pharma, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 03, 2017, 08:00 ET aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

Mar 16, 2017, 16:05 ET aTyr Pharma Announces Fourth Quarter and Year-End 2016 Operating Results

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

Mar 15, 2017, 06:00 ET aTyr Pharma Announces Issuance of US Patent That Extends Patent Protection of Physiocrines Derived From 20 out of 20 Human tRNA Synthetases

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

Mar 03, 2017, 07:00 ET aTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris™

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

Mar 01, 2017, 07:00 ET aTyr Pharma to Present at Cowen and Company 37th Annual Health Care Conference

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

Feb 28, 2017, 07:00 ET aTyr Pharma Receives U.S. FDA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris™

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

Jan 18, 2017, 07:00 ET FDA Grants Fast Track Designation for aTyr's Resolaris™ to Treat Limb Girdle Muscular Dystrophy 2B and Removes Partial Clinical Hold for Resolaris

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

Jan 04, 2017, 08:00 ET aTyr Pharma to Present at 35th Annual J.P. Morgan Healthcare Conference

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

Dec 13, 2016, 07:00 ET aTyr Pharma Reports Promising Signals of Clinical Activity in Multiple Rare Genetically Distinct Myopathies with Resolaris™ in Exploratory Trials

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

Dec 09, 2016, 09:00 ET aTyr Pharma to Present at the BMO Prescriptions for Success Healthcare Conference

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

Nov 21, 2016, 08:00 ET aTyr Pharma Enters into $20 Million Credit Facility

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

Nov 14, 2016, 07:30 ET aTyr Pharma Announces Third Quarter 2016 Operating Results

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

Nov 03, 2016, 08:00 ET aTyr Pharma to Present at Three Upcoming Conferences in November

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

Oct 24, 2016, 08:00 ET aTyr Pharma Receives FDA Fast Track Designation for Resolaris™ to Treat Facioscapulohumeral Muscular Dystrophy (FSHD)

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

Oct 06, 2016, 09:00 ET aTyr Pharma Presents Additional Data for Resolaris™ Phase 1b/2 Trial in Adult Patients with Facioscapulohumeral Muscular Dystrophy at the 21st International Annual Congress of the World Muscle Society

aTyr Pharma, Inc. (Nasdaq: LIFE), today announced that additional clinical data from aTyr's Phase 1b/2 Trial (002) in adult patients with FSHD were...

Sep 29, 2016, 08:30 ET aTyr Pharma Announces Presentation at the 21st International Annual Congress of the World Muscle Society

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

Sep 21, 2016, 05:00 ET aTyr Pharma Appoints Industry Veteran in Novel Biology Biologics, David J. King, PhD, as Senior Vice President, Research

aTyr Pharma, Inc. (Nasdaq: LIFE), today announced that David J. King, PhD, has joined the company as Senior Vice President, Research. Dr. King will...

Aug 10, 2016, 04:05 ET aTyr Pharma Announces Second Quarter 2016 Operating Results

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

Jun 03, 2016, 07:30 ET aTyr Pharma to Present at Jefferies 2016 Healthcare Conference

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

May 11, 2016, 04:01 ET aTyr Pharma Announces First Quarter 2016 Operating Results

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

May 05, 2016, 07:30 ET aTyr Pharma Appoints Grove Matsuoka as Senior Vice President, Product Programs and Planning

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

Apr 29, 2016, 09:09 ET aTyr Pharma to Present at Upcoming May Investor Conferences

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

Apr 06, 2016, 08:07 ET aTyr Pharma to Present at 15th Annual Needham & Company Healthcare Conference

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

Mar 30, 2016, 04:03 ET aTyr Pharma Announces Fourth Quarter 2015 Operating Results

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...

Mar 30, 2016, 04:02 ET aTyr Pharma Announces Encouraging Phase 1b/2 Results for Resolaris™ in its First Rare Myopathy Trial

aTyr Pharma, Inc. (Nasdaq: LIFE) a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address...